Stock Events

Stock Events

CalciMedica 

$0.58
18
+$0.04+7.78% Today

Statistics

Day High
0.6
Day Low
0.54
52W High
7.2
52W Low
0.46
Volume
49,827
Avg. Volume
1,249,818
Mkt Cap
8.39M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.68
-0.55
-0.41
-0.28
Expected EPS
-0.28
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-27.4MNet Income

Analyst Ratings

$10.00Average Price Target
The highest estimate is 10.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
50%
Hold
50%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CALC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals is involved in the development of small molecule drugs for serious diseases, including inflammatory conditions, which puts it in direct competition with CalciMedica's focus on treatments for acute pancreatitis and other inflammatory diseases.
Gilead Sciences
GILD
Mkt Cap148.78B
Gilead Sciences focuses on antiviral drugs for infections like HIV, hepatitis B, hepatitis C, and influenza, but its expansion into other therapeutic areas, including inflammatory and respiratory diseases, makes it a competitor.
Abbvie
ABBV
Mkt Cap385.18B
AbbVie operates in areas including immunology and chronic inflammatory conditions, directly competing with CalciMedica's development of treatments for diseases with inflammatory components.
AMGEN
AMGN
Mkt Cap160.66B
Amgen focuses on human therapeutics, including treatments for inflammatory diseases, making it a competitor in the biopharmaceutical space targeting similar conditions as CalciMedica.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals specializes in medicines for serious conditions, with a significant focus on inflammatory diseases, positioning it as a competitor to CalciMedica.
Biogen
BIIB
Mkt Cap22.63B
Biogen focuses on developing therapies for neurological and neurodegenerative diseases, but its interest in expanding into other areas, including inflammatory diseases, makes it a potential competitor.
Novartis
NVS
Mkt Cap237.61B
Novartis is a global healthcare company that operates across various segments, including pharmaceuticals that target inflammatory diseases, making it a competitor in the same therapeutic area as CalciMedica.
Pfizer
PFE
Mkt Cap140.15B
Pfizer develops and produces medicines and vaccines for a wide range of medical disciplines, including inflammation and immunology, directly competing with CalciMedica's focus areas.
Johnson & Johnson
JNJ
Mkt Cap455.04B
Johnson & Johnson, through its pharmaceutical segment, develops treatments for a broad range of health conditions, including inflammatory diseases, making it a competitor.
Astrazeneca
AZN
Mkt Cap256.58B
AstraZeneca operates in several key therapeutic areas, including respiratory, inflammation, and autoimmunity, positioning it as a competitor to CalciMedica in the inflammation segment.

About

CalciMedica, Inc., a clinical-stage biotechnology company, focuses on developing therapies for life-threatening inflammatory diseases with unmet needs. Its proprietary technology targets the inhibition of calcium release-activated (CRAC) channels designs to modulate the immune response and protect against tissue cell injury in life-threatening inflammatory diseases. Its lead product candidate is Auxora, a proprietary intravenous-formulated CRAC channel inhibitor for the treatment of acute pancreatitis, asparaginase-associated acute pancreatitis, and acute kidney injury. The company is based in La Jolla, California.
Show more...
CEO
Dr. A. Rachel Leheny Ph.D.
Employees
14
Country
US
ISIN
US38942Q2021

Listings

XNAS
US
CALC
BOATS
BOATS
CALC.BOATS

0 Comments

Share your thoughts

FAQ

What is CalciMedica stock price today?▼
The current price of CALC is $0.58 USD — it has increased by +7.78% in the past 24 hours. Watch CalciMedica stock price performance more closely on the chart.
What is CalciMedica stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange CalciMedica stocks are traded under the ticker CALC.
Is CalciMedica stock price growing?▼
CALC stock has fallen by -1.91% compared to the previous week, the month change is a +9.43% rise, over the last year CalciMedica has showed a -71.03% decrease.
What is CalciMedica market cap?▼
Today CalciMedica has the market capitalization of 8.39M
When is the next CalciMedica earnings date?▼
CalciMedica is going to release the next earnings report on May 18, 2026.
What were CalciMedica earnings last quarter?▼
CALC earnings for the last quarter are -0.68 USD per share, whereas the estimation was -0.41 USD resulting in a -64.85% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is CalciMedica revenue for the last year?▼
CalciMedica revenue for the last year amounts to 0 USD.
What is CalciMedica net income for the last year?▼
CALC net income for the last year is -27.4M USD.
How many employees does CalciMedica have?▼
As of April 01, 2026, the company has 14 employees.
In which sector is CalciMedica located?▼
CalciMedica operates in the Health Care sector.
When did CalciMedica complete a stock split?▼
The last stock split for CalciMedica was on March 20, 2023 with a ratio of 1:14.
Where is CalciMedica headquartered?▼
CalciMedica is headquartered in La Jolla, US.